Cytox Group

Cytox Limited was a UK biotechnology business that developed genetic risk assessment tools for Alzheimer’s disease and dementia research. Its genoSCORE™ technology used polygenic risk scoring to estimate genetic susceptibility to late-onset Alzheimer’s disease using genetic information from blood or saliva samples.

The company also developed solutions intended to help pharmaceutical and biotechnology companies stratify candidates for clinical trials, investigate cognitive decline and assess genetic factors associated with disease progression. Its commercial model included partnerships with clinical laboratories and healthcare organizations.

Current-status qualification: Companies House records Cytox Limited as being in liquidation, with winding-up commencing on 4 January 2024. The description above summarizes its historical business and products rather than confirming that Cytox Limited currently operates.